ArticleScientific reports2022

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.

Magda S C Fontes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.